BioSpace News Archive

DBV Technologies, a clinical-stage biopharmaceutical company, held its Ordinary and Extraordinary General Meeting.

Arcutis Biotherapeutics, Inc., an early-stage commercial company focused on developing meaningful innovations in immuno-dermatology, announced that Arcutis management will participate in an upcoming investor conference.

ViewRay, Inc. (NASDAQ: VRAY) will hold a conference call to discuss results on Thursday, April 13, 2023, at 8:00 AM ET.

Flexan LLC announced that it is expanding its services to include custom manufacturing of sterile liquids and custom formulated solutions for a variety of medical device applications.

Viatris Inc. (NASDAQ: VTRS) plans to report its first quarter 2023 financial results on Monday, May 8 before the open of the U.S. financial markets.

Medidata, a Dassault Systèmes company, today announced that Launch Therapeutics selected Medidata AI Intelligent Trials to support its innovative approach to accelerating clinical trials of late-stage therapies.

Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company leading the discovery and development of allosteric small molecule therapies, today announced the appointment of C. Evan Ballantyne as the Company’s Chief Financial Officer, effective immediately.

GlucoTrack, Inc., a medical device and digital health platform company focused on diabetes and prediabetes, announced that it intends to offer shares of common stock in a firm commitment underwritten public offering.

Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that Chief Medical Officer Thomas Heineman , M.D., Ph.D., will participate in the Viral Immunotherapy – Moving Forward panel at Canaccord Genuity’s Horizons in Oncology Virtual Conference, which is taking place virtually on April 20, 2023.

Adaptive Biotechnologies Corporation today announced it has entered into a translational collaboration with Takeda to use its clonoSEQ ® Assay to assess minimal residual disease (MRD) to facilitate the development and commercialization of Takeda’s pipeline of treatments for patients with lymphoid malignancies.